Latest News

  • PARIS, France and CAMBRIDGE, MA, USA  – Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically: Sanofi will obtain global development and commercialization rights...
  • VANCOUVER, British Columbia – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, provided key accomplishments from the past year and announced priorities for 2018. “2017 was a great year for Zymeworks and we are poised to achieve a number of important corporate milestones in 2018,” said Ali Tehrani,...
  • Alzheimer’s disease is a devastating brain illness that affects an estimated 47 million people worldwide. It is the most common cause of dementia in the Western world. Despite this, there are currently no treatments that are effective in curing Alzheimer’s disease or preventing its relentless progression. Alzheimer’s disease is caused...

Videos

Rare disease spotlight

Twitter

The @NA4Caregiving invites caregivers and grassroots advocates to attend a townhall on Tuesday, December 1st 3-5 pm ET. To register: https://conta.cc/2J4YWv9

We are so excited to feature an incredible lineup of community artists for PPMD’s Community Concert: Harmony Together tomorrow evening, November 22 at 7 PM EST! Meet our featured community artists: https://www.parentprojectmd.org/ppmds-community-concert-harmony-together/

AVROBIO is now enrolling males with classic #Fabry disease for a Phase 1/2 clinical trial to study AVR-RD-01. To learn more and find out if you’re eligible, contact 1-877-330-5216 and visit http://www.AVROBIOfabrytrial.com.

Load More...